Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PHN-012 in Advanced Solid Tumors
NCT07127874Phase 1Recruiting
- Sponsor
- Pheon Therapeutics
- Start
- Sep 2025
- Primary completion
- Sep 2027
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of PHN-012 in colorectal cancer (CRC), non-small cell lung cancer (NSCLC) and pancreatic cancer (PC), sponsored by Pheon Therapeutics. Primary endpoints: Incidence of dose limiting toxicities at 12 months, Type, incidence and severity of adverse events and serious adverse events at 12 months and 2 more. Started Sep 2025; status: recruiting.
02
Drugs
PHN-012
03
Conditions
colorectal cancer (CRC)non-small cell lung cancer (NSCLC)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT07127874.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07127874.